Leaders | Big tech

How to make sense of the latest tech surge

The big tech firms’ shares have been on a tear

IN 2018 A new word entered Silicon Valley’s lexicon: the “techlash”, or the risk of a consumer and regulatory revolt against big tech. Today that threat seems empty. Even as regulators discuss new rules and activists fret about the right to privacy, the shares of the five biggest American tech firms have been on a jaw-dropping bull run over the past 12 months, rising by 52%. The increase in the firms’ combined value, of almost $2trn, is hard to get your head round: it is roughly equivalent to Germany’s entire stockmarket. Four of the five—Alphabet, Amazon, Apple and Microsoft—are each now worth over $1trn. (Facebook is worth a mere $620bn.) For all the talk of a techlash, fund managers in Boston, London and Singapore have shrugged and moved on. Their calculus is that nothing can stop these firms, which are destined to earn untold riches.

This article appeared in the Leaders section of the print edition under the headline “Big tech’s $2trn bull run”

Big tech’s $2trn bull run

From the February 22nd 2020 edition

Discover stories from this section and more in the list of contents

Explore the edition

More from Leaders

Keir Starmer surrounded by the Eu stars

Sir Keir Starmer should aim higher in his reset with the EU

And he needs to be clearer about what Britain wants

illustration of a world map outlined by a single red electrical cord, with a plug at one end and a socket at the other

To make electricity cheaper and greener, connect the world’s grids

Less than 3% of the world’s power is internationally traded—a huge wasted opportunity


Chinese AI is catching up, posing a dilemma for Donald Trump

The success of cheap Chinese models threatens America’s technological lead


America has an imperial presidency

And in Donald Trump, an imperialist president for the first time in over a century

Tariffs will harm America, not induce a manufacturing rebirth

Donald Trump’s pursuit of tariffs will make the world poorer—and America, too 

How to improve clinical trials

Involving more participants can lead to new medical insights